What is Immix Biopharma, Inc.'s remainder of fiscal year 2024?

Immix Biopharma, Inc. (IMMX) reported remainder of fiscal year 2024 of $162.73K in Q1 2026.

How has Immix Biopharma, Inc.'s remainder of fiscal year 2024 changed year-over-year?

Immix Biopharma, Inc.'s remainder of fiscal year 2024 increased by 46.8% year-over-year, from $110.85K to $162.73K.

Immix Biopharma, Inc. IMMX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Allogene TherapeuticsALLO

——

PrecigenPGEN

——

Artiva Biotherapeutics, Inc.ARTV

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$10.8M-131%

Net income-$10.1M-122%

EPS (diluted)-$0.18-20.0%

Balance sheet

See full

Cash & equivalents$79.3M+398%

Total debt$1.0M-2.0%

Total equity$84.4M+779%

Total assets$95.8M+382%

Cash flow

See full

Operating cash flow-$9.8M-483%

CapEx$32.5K-52.0%

Free cash flow-$9.9M-462%

Valuation

See full

Market cap$691.97M+1,008%

Enterprise value$613.75M+1,190%

Returns & leverage

See full

Return on equity-74.4%-18.6pp

Debt / equity0×-0.1×

Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immix Biopharma, Inc.'s remainder of fiscal year 2024?: Immix Biopharma, Inc. (IMMX) reported remainder of fiscal year 2024 of $162.73K in Q1 2026.
How has Immix Biopharma, Inc.'s remainder of fiscal year 2024 changed year-over-year?: Immix Biopharma, Inc.'s remainder of fiscal year 2024 increased by 46.8% year-over-year, from $110.85K to $162.73K.